Source: Lasker Foundation | April 25, 2018 Rachel Cohen is the regional executive director of the Drugs for Neglected Diseases initiative (DNDi), a nonprofit drug research and development organization focused on diseases such as leishmaniasis and sleeping sickness. Previously, she worked … Continue reading
The FDA has a smart-sounding program to drive research for neglected diseases—with two big flaws. Politico; March 25, 2016. By Willo Brock, Rachel Cohen, Jason Cone and Lindsay McKenna. Last week, the Senate voted to add Zika to the list of neglected … Continue reading
IP Watch; December 8, 2015. A newly issued report provides the “first ever” picture of global investment in Ebola research and development. The report found that investment in Ebola might have come at the expense of other funding to develop drugs, … Continue reading
KaloBios, a once-doomed company brought back from the brink by biotech entrepreneur Martin Shkreli, bought the rights to an old antiparasitic drug with hopes of winning FDA approval and securing one of the agency’s valuable priority review vouchers.
MSF, November 19, 2015. On November 17, 2015, Doctors Without Borders/Médecins Sans Frontières (MSF), the American Thoracic Society, the Drugs for Neglected Diseases initiative (DNDi), the Global Alliance for TB Drug Development, the IDSA Center for Global Health Policy, the Sabin … Continue reading
The Guardian; October 30, 2015. What does it take to bring the fruits of scientific innovation to vulnerable patients in the world’s poorest communities? The discoveries recognised by the 2015 Nobel prize for medicine are perfect examples of the journey from test … Continue reading
SciDevNet; November 2, 2015. One of the most effective treatments for snakebite could run out in June 2016, putting the lives of tens of thousands of people in Sub-Saharan Africa at risk, Médecins Sans Frontières (MSF) has warned. The French … Continue reading